MYGN
Closed
Myriad Genetics Inc
5.53
+0.22 (+4.14%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 5.31
Day's Range: 5.23 - 5.7401
Send
sign up or login to leave a comment!
When Written:
23.33
Myriad Genetics Inc is a biotechnology company that specializes in developing and marketing molecular diagnostic tests for various diseases, including cancer. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Myriad Genetics is best known for its BRACAnalysis test, which is used to detect mutations in the BRCA1 and BRCA2 genes that increase the risk of breast and ovarian cancer. The company also offers other genetic tests for cancer, as well as tests for cardiovascular disease, neurological disorders, and other conditions.
In addition to its diagnostic testing business, Myriad Genetics also has a pharmaceutical division that focuses on developing targeted therapies for cancer and other diseases. The company has partnerships with several other biotech and pharmaceutical companies to develop and commercialize its products.
Myriad Genetics has faced some controversy over its patents on the BRCA genes, which have been challenged in court by critics who argue that gene sequences should not be patentable. Despite these challenges, the company has continued to grow and expand its product offerings.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Myriad Genetics is best known for its BRACAnalysis test, which is used to detect mutations in the BRCA1 and BRCA2 genes that increase the risk of breast and ovarian cancer. The company also offers other genetic tests for cancer, as well as tests for cardiovascular disease, neurological disorders, and other conditions.
In addition to its diagnostic testing business, Myriad Genetics also has a pharmaceutical division that focuses on developing targeted therapies for cancer and other diseases. The company has partnerships with several other biotech and pharmaceutical companies to develop and commercialize its products.
Myriad Genetics has faced some controversy over its patents on the BRCA genes, which have been challenged in court by critics who argue that gene sequences should not be patentable. Despite these challenges, the company has continued to grow and expand its product offerings.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








